Comparative Pharmacology
Head-to-head clinical analysis: MAXIPIME versus ROCEPHIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAXIPIME versus ROCEPHIN.
MAXIPIME vs ROCEPHIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefepime is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking. It has enhanced activity against Gram-negative bacteria due to rapid penetration through the outer membrane and low affinity for β-lactamases.
Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby interfering with peptidoglycan cross-linking and leading to cell lysis.
1-2 g IV every 8-12 hours for most indications; maximum 2 g every 8 hours for severe infections.
1-2 g IV or IM every 24 hours; maximum 4 g/day for serious infections.
None Documented
None Documented
Terminal elimination half-life is approximately 2-2.5 hours in adults with normal renal function; extends to 8-12 hours in moderate renal impairment (CrCl 30-60 mL/min) and up to 20-24 hours in severe impairment (CrCl < 30 mL/min).
Terminal half-life ~6-8 hours in adults with normal renal function; prolonged to 12-24 hours in neonates and elderly.
Primarily renal (approximately 80-90% as unchanged drug) via glomerular filtration and tubular secretion; biliary/fecal excretion is minimal (< 1%).
Renal (33-67%) and biliary (40-50%); primarily excreted unchanged. Dual elimination: ~50% renal, ~50% biliary/fecal.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic